Immunitybio is trading 4.3% down at $7.93 amid broader market weakness and heightened geopolitical risk.
- The Nasdaq and Dow are each down more than 0.5%, while surging oil prices and U.S.-Iran tensions pressure risk appetite.
- No new September 9, 2026 company-specific announcement, filing, earnings report, or analyst action was identified.
- Recent Immunitybio news remains positive, including record second-quarter revenue reported August 4.